Financial Performance Summary - In 2025, the company achieved operating revenue of 664.39 million yuan, an increase of 178.88 million yuan, representing a year-on-year growth of 36.84% [2] - The net profit attributable to the parent company was -155.01 million yuan, a deterioration of 53.17 million yuan compared to the previous year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -157.87 million yuan, worsening by 64.78 million yuan year-on-year [2] Asset and Equity Status - As of the end of the reporting period, total assets amounted to 3,371.04 million yuan, reflecting a growth of 10.95% from the beginning of the year [2] - The equity attributable to the parent company was 1,276.86 million yuan, a decrease of 6.11% from the beginning of the year [2] Revenue Growth Factors - The increase in operating revenue was primarily driven by a rise in semiconductor packaging and testing sales, which increased by 94.32 million yuan, and semiconductor acousto-optic sales, which rose by 88.79 million yuan [2] - The company began mass production and delivery of semiconductor process bonding prisms in November 2025, contributing an additional 10.97 million yuan to sales [2] - Small-scale production of MEMS devices (MicroLED, uncooled infrared) also contributed an increase of 4.26 million yuan in sales [2] Cost and Expense Analysis - The company recognized share-based payment expenses of 43.21 million yuan due to the implementation of an equity incentive plan, an increase of 38.05 million yuan from the previous year [3] - Interest expenses rose to 40.45 million yuan, an increase of 13.82 million yuan, due to larger fixed asset investments and corresponding borrowings [3] - Depreciation expenses increased to 207.37 million yuan, up by 57.58 million yuan, as new processes and products entered the gradual mass production phase [3] - Labor costs rose to 184.67 million yuan, an increase of 36.38 million yuan, due to increased personnel needs across production and technology [3] - Research and development expenses were approximately 136.61 million yuan, an increase of 28.89 million yuan from the previous year [4] Significant Changes in Financial Metrics - The company's operating revenue increased by 36.84%, while operating profit, total profit, net profit attributable to the parent company, and net profit after deducting non-recurring gains and losses all saw declines exceeding 30% [5]

Group 1: Transaction Overview - The company plans to introduce strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership) through its subsidiary Zhejiang Meidikai Optical Semiconductor Co., Ltd. [2] - The board of directors approved the proposal for capital increase and share expansion on December 10, 2025, and the relevant agreements have been signed [3]. Group 2: Transaction Progress - As of the announcement date, the company and related parties have signed the capital increase agreement and shareholder agreement, with a total cash capital increase of RMB 200 million received [3]. - Following the capital increase, the registered capital of the optical semiconductor company will increase from RMB 1,008,888,889 to RMB 1,101,447,503, and the company's shareholding will change to 82.44% [3]. Group 3: Performance Forecast - For the fiscal year 2025, the company expects to achieve approximately RMB 664.26 million in revenue, a year-on-year increase of 36.82% [8]. - The company anticipates a net loss attributable to shareholders of approximately RMB -154.41 million, a decrease of RMB 52.57 million compared to the previous year [8]. - EBITDA is projected to be around RMB 65.29 million, reflecting a year-on-year increase of 19.62% [8]. Group 4: Revenue Growth Factors - The revenue increase is attributed to higher sales in semiconductor packaging and testing, as well as new product launches contributing to additional revenue [14]. - Specific revenue contributions include an increase of approximately RMB 94.32 million from semiconductor packaging and testing and RMB 88.90 million from semiconductor acousto-optics [14]. Group 5: Cost and Expense Increases - The company has incurred higher costs due to stock incentive plans, increased interest expenses from larger borrowings, and rising depreciation costs from fixed asset investments [15][16]. - Research and development expenses have also increased, reflecting the company's commitment to new technologies and products [16].

Core Viewpoint - Medike (688079.SH) expects a significant increase in revenue for 2025, while net profit is projected to decline, indicating a mixed financial outlook for the company [1] Financial Projections - The company anticipates achieving an operating revenue of approximately 664.257 million yuan in 2025, representing an increase of about 178.746 million yuan or 36.82% year-on-year [1] - The projected net profit attributable to the parent company is expected to be around -154.414 million yuan, a decrease of approximately 52.568 million yuan compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is estimated to be around -156.947 million yuan, reflecting a decline of about 63.860 million yuan year-on-year [1] Revenue Drivers - The increase in revenue is primarily driven by a rise in semiconductor packaging and testing sales, which are expected to increase by approximately 94.322 million yuan [1] - Sales from semiconductor acousto-optic products are projected to rise by about 88.898 million yuan [1] - The company will begin mass production and delivery of semiconductor process bonding prisms in November 2025, contributing an additional revenue of around 10.969 million yuan [1] - Small-scale production of MEMS devices (MicroLED, uncooled infrared) is expected to generate an increase in sales revenue of approximately 4.256 million yuan [1]